drugset / Trial / NCT06818058
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.
Timeline
- Start
- 2025-01-20
- Primary completion
- 2026-09-01
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | — | Topical |
Indications
No indication recorded.